ABSTRACT
【Objective】 To summarize and analyze the clinical data of fumarate hydrase-deficient renal cell carcinoma (FH-RCC), so as to improve the understanding of the disease. 【Methods】 General clinical data of 12 FH-RCC patients treated during Mar.2019 and Dec.2021 were retrospectively analyzed, including the imaging, pathological, genetic testing, surgical and adjuvant therapy, and follow-up results. 【Results】 All cases were confirmed with pathology or genetic tests, including 1 case complicated with uterine fibroids, 3 cases with renal cysts, 4 with family history of uterine fibroids and 2 with family history of renal carcinoma. Cysticular irregular density shadows with an enhancement of 25.8 Hu were detected in 4 cases. Of the 7 cases undergoing genetic testing, 2 had embryo and system mutation, 1 had germ line mutation, 1 had system mutation, and 3 had no germ line or system mutation. Radical nephrotomy was performed in 9 cases. The average operation time was 3.8 h, and the average amount of blood loss was 625 mL. Immunotherapy with targeted therapy was conducted in 10 cases, surgery with postoperative adjuvant therapy in 7 cases, and tyrosine kinase inhibitor with immune checkpoint inhibitor (TKI/ICI) in 1 case. All 12 cases were followed up, 3 died of tumor, 1 had no recurrence, 8 showed progress on imaging. 【Conclusion】 FH-RCC is a rare and highly malignancy prone to metastasis. Imaging shows cystic solid space occupying lesions. FH immunohistochemical staining is negative. Genetic testing is needed to confirm the diagnosis. TKI/ICI combination therapy has a good survival benefit.
ABSTRACT
The many-banded krait, Bungarus multicinctus, has been recorded as the animal resource of JinQianBaiHuaShe in the Chinese Pharmacopoeia. Characterization of its venoms classified chief phyla of modern animal neurotoxins. However, the evolutionary origin and diversification of its neurotoxins as well as biosynthesis of its active compounds remain largely unknown due to the lack of its high-quality genome. Here, we present the 1.58 Gbp genome of B. multicinctus assembled into 18 chromosomes with contig/scaffold N50 of 7.53 Mbp/149.8 Mbp. Major bungarotoxin-coding genes were clustered within genome by family and found to be associated with ancient local duplications. The truncation of glycosylphosphatidylinositol anchor in the 3'-terminal of a LY6E paralog released modern three-finger toxins (3FTxs) from membrane tethering before the Colubroidea divergence. Subsequent expansion and mutations diversified and recruited these 3FTxs. After the cobra/krait divergence, the modern unit-B of β-bungarotoxin emerged with an extra cysteine residue. A subsequent point substitution in unit-A enabled the β-bungarotoxin covalent linkage. The B. multicinctus gene expression, chromatin topological organization, and histone modification characteristics were featured by transcriptome, proteome, chromatin conformation capture sequencing, and ChIP-seq. The results highlighted that venom production was under a sophisticated regulation. Our findings provide new insights into snake neurotoxin research, meanwhile will facilitate antivenom development, toxin-driven drug discovery and the quality control of JinQianBaiHuaShe.
ABSTRACT
Objective To analyse the clinical usage of Shenmai injection, promote the rational use of Shenmai injection. Methods 400 hospital medical records that used Shenmai injection in 2015 were collected and reviewed from hospital information system (HIS) by retrospective analysis method, aggregated and evaluated data by EXCEL. Results In 400 cases, 11 clinical departments used the Shenmai injection, mainly in cardiology of 347 cases(86.75%).The percentage of the non-standard clinical application of Shenmai injection was 84 cases (21.00%). The non-standardized rates of solvent dispensing was 287 cases (71.75%), and the specification incompatibility accounted for 105 cases (26.25%). There was no adverse drug reaction of Shenmai injection. Conclusion The clinical use of Shenmai injection is not yet standardized, which suggests that drugs should be strictly used in accordance with the instruction, in order to avoid risks of off-label use.
ABSTRACT
@# Objective To analyse the effect of microwave therapy on tennis elbow. Methods 60 patients with tennis elbow during September, 2007 to September, 2008 were divided into treatment group and control group. The treatment received microwave therapy while control group was treated with Diclofenac Diethylamine. All patients were evaluated by Visual Analogue Scale (VAS) before and after the treatment.Results The VAS is lower in the treatment group than in the control group(P<0.01). Conclusion Microwave therapy is effective on tennis elbow.